Search

everythinglearnresearchcommunity

for

Search:↓

The European Society of Endocrinology advises individualized long-term management for PCOS, focusing on lifestyle changes, accurate diagnosis, and treatments for associated health risks and symptoms.

PCOS is a common hormonal disorder in women, marked by symptoms like hair growth and menstrual issues, and requires personalized treatment.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

The document concludes that careful evaluation is needed to diagnose PCOS correctly due to similar symptoms in other conditions, and accurate testosterone level measurement is crucial.

Skin health and diseases are closely linked to metabolic processes.

The document concludes that treating skin conditions should include psychological care and a multidisciplinary approach is essential for effective management.

Polycystic ovary syndrome (PCOS) is a major health issue for women in Egypt, affecting 14% of fertile women and 37.5% of infertile women.

Two new reliable Arabic questionnaires for measuring quality of life in women with PCOS were created, one for married and one for unmarried women.

Oxidative stress is higher in women with PCOS, especially if they're obese, and it may increase their risk of heart disease.

Hypothyroidism may worsen metabolic problems like insulin resistance and obesity in women with PCOS.

Non-classical 21 hydroxylase deficiency is an underdiagnosed cause of female hair loss and polycystic ovarian syndrome.

Finasteride and dutasteride can cause severe, lasting side effects.

The 2018 guideline for PCOS suggests new diagnostic criteria and treatments, but recognizes the need for more research.

Oxidative stress worsens PCOS by damaging cells and disrupting metabolism, suggesting antioxidant treatments might help.

The guideline provides healthcare professionals in South Africa with instructions for comprehensive, multidisciplinary gender-affirming care, including HIV prevention and treatment for transgender and gender diverse individuals.

PCOS causes infertility mainly due to hormonal imbalances, insulin resistance, and chronic inflammation.

Obesity leads to physical, metabolic, reproductive issues, higher healthcare costs, and mental health problems.

Lifestyle changes like a healthy diet, exercise, and proper sleep can help manage PCOD.

Polycystic Ovary Syndrome (PCOS) affects 6%-15% of women of reproductive age, causing symptoms like acne and hair loss, and increasing the risk of type 2 diabetes and heart disease; it's managed through diet, exercise, and medications like Metformin and hormonal contraceptives.

Higher levels of unbound testosterone are linked to increased insulin resistance, especially in women with polycystic ovary syndrome.

Spironolactone can reduce hair growth in women with hirsutism.

Women with PCOS are more likely to have sleep apnea, mainly if they are obese.

Cimetidine did not reduce hair growth in women with hirsutism.

Flutamide is more effective and has fewer side effects than spironolactone for treating hirsutism.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Finasteride reduces hair growth better, but spironolactone has more side effects.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Teens with PCOS and a mom with PCOS have higher insulin resistance and lower adiponectin levels, which could signal early metabolic problems.